China's National Medical Products Administration has cleared the clinical trial application for Mabwell's innovative LILRB4/CD3-targeting bispecific antibody 6MW5311, advancing the company's oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results